Great West Life Assurance Co. Can bought a new stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) during the third quarter, according to its most recent filing with the SEC. The firm bought 24,710 shares of the company's stock, valued at approximately $470,000. Great West Life Assurance Co. Can owned about 0.07% of iTeos Therapeutics at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Prairiewood Capital LLC acquired a new position in iTeos Therapeutics in the 3rd quarter valued at $615,000. Alps Advisors Inc. acquired a new position in iTeos Therapeutics in the 2nd quarter valued at $434,000. Rafferty Asset Management LLC grew its stake in iTeos Therapeutics by 2.1% in the 2nd quarter. Rafferty Asset Management LLC now owns 99,368 shares of the company's stock valued at $2,047,000 after buying an additional 2,067 shares during the last quarter. Principal Financial Group Inc. grew its stake in iTeos Therapeutics by 22.7% in the 2nd quarter. Principal Financial Group Inc. now owns 167,750 shares of the company's stock valued at $3,455,000 after buying an additional 31,004 shares during the last quarter. Finally, Virtus ETF Advisers LLC grew its stake in iTeos Therapeutics by 39.1% in the 2nd quarter. Virtus ETF Advisers LLC now owns 5,790 shares of the company's stock valued at $119,000 after buying an additional 1,629 shares during the last quarter.
Get iTeos Therapeutics alerts:iTeos Therapeutics Trading Up 2.3 %
NASDAQ:ITOS opened at $20.77 on Friday. iTeos Therapeutics, Inc. has a 1 year low of $16.21 and a 1 year high of $37.88. The firm's fifty day simple moving average is $19.88 and its 200 day simple moving average is $20.92. The firm has a market capitalization of $739.00 million, a PE ratio of 3.02 and a beta of 1.37.
iTeos Therapeutics (NASDAQ:ITOS – Get Rating) last posted its quarterly earnings results on Thursday, November 10th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.04). The company had revenue of $19.49 million during the quarter, compared to analyst estimates of $42.05 million. iTeos Therapeutics had a return on equity of 42.62% and a net margin of 57.48%. As a group, analysts anticipate that iTeos Therapeutics, Inc. will post 2.85 EPS for the current fiscal year.iTeos Therapeutics Company Profile
(Get Rating)
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
See Also
- Get a free copy of the StockNews.com research report on iTeos Therapeutics (ITOS)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
Want to see what other hedge funds are holding ITOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating).
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.